What is Cara Care?
Headquartered in Berlin, Germany, Cara Care operates at the intersection of medical expertise and digital innovation. The company provides a specialized mobile platform designed to assist patients in managing gastrointestinal disorders through symptom tracking, dietary guidance, and direct access to medical specialists. By bridging the gap between clinical care and daily patient management, Cara Care addresses a significant market need for accessible, evidence-based digital health solutions. With a workforce of 50 to 99 professionals and a revenue profile between 1M and 5M, the company has demonstrated a sustainable business model that effectively integrates patient-centric design with rigorous medical standards.
How much funding has Cara Care raised?
Cara Care has raised a total of $7M across 1 funding round:
Series A
$7M
Series A (2022): $7M with participation from Asabys Partners, Johnson & Johnson Services Inc, and Atlantic Labs
Key Investors in Cara Care
Asabys Partners
Asabys Partners is an investment firm based in Barcelona that focuses on fostering breakthrough innovation in healthcare and life sciences, aiming to improve patients' lives through disruptive advancements in science and medicine.
Johnson & Johnson Services Inc
Johnson & Johnson is a global healthcare company that develops pharmaceuticals and medical technologies, providing innovative medicines and surgical products used in areas such as oncology, immunology, and cardiovascular care.
Atlantic Labs
Atlantic Labs is a Berlin-based venture capital firm that specializes in early-stage investments, focusing on supporting ambitious founders building transformative technology companies in the European ecosystem.
What's next for Cara Care?
Looking ahead, the strategic deployment of this capital will likely focus on enhancing the platform's diagnostic capabilities and deepening integration with existing healthcare systems. As the company transitions from its current growth phase toward broader market penetration, the focus will shift to clinical validation and regulatory expansion. The backing from high-profile institutional investors provides not only the necessary liquidity for scaling but also access to a vast network of healthcare expertise. Cara Care is poised to leverage these partnerships to refine its therapeutic algorithms and potentially explore new indications within the broader chronic disease management market, ensuring long-term value creation for both patients and stakeholders.
See full Cara Care company page
